GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » DA32 Life Science Tech Acquisition Corp (NAS:DALS) » Definitions » Long-Term Capital Lease Obligation

DA32 Life Science Tech Acquisition (DA32 Life Science Tech Acquisition) Long-Term Capital Lease Obligation : $0.00 Mil (As of Mar. 2023)


View and export this data going back to 2021. Start your Free Trial

What is DA32 Life Science Tech Acquisition Long-Term Capital Lease Obligation?

DA32 Life Science Tech Acquisition's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.00 Mil.


DA32 Life Science Tech Acquisition Long-Term Capital Lease Obligation Historical Data

The historical data trend for DA32 Life Science Tech Acquisition's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DA32 Life Science Tech Acquisition Long-Term Capital Lease Obligation Chart

DA32 Life Science Tech Acquisition Annual Data
Trend Dec21 Dec22
Long-Term Capital Lease Obligation
- -

DA32 Life Science Tech Acquisition Quarterly Data
Apr21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial - - - - -

DA32 Life Science Tech Acquisition  (NAS:DALS) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

DA32 Life Science Tech Acquisition Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of DA32 Life Science Tech Acquisition's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


DA32 Life Science Tech Acquisition (DA32 Life Science Tech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
345 Park Avenue South, 12th Floor, New York, NY, USA, 10010
Website
DA32 Life Science Tech Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Executives
Da32 Sponsor Llc 10 percent owner 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Management Company, L.p. (series C) director, 10 percent owner, other: Director by deputization 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Arch Venture Fund Xi, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Section 32 Fund 3, Lp 10 percent owner, other: Director by Deputization 169 UNIVERSITY AVE., PALO ALTO CA 94301
Keith Crandell director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
William J Maris 10 percent owner, other: Director by Deputization 2033 SAN ELIJO AVE., #565, CARDIFF-BY-THE-SEA CA 92007
Angela Lai director 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Arch Venture Partners Xi, Llc 10 percent owner 8755 W HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Xi, L.p. 10 percent owner 8755 W HIGGINS RD., SUITE 1025, CHICAGO IL 60631
Section 32 Gp 3, Llc 10 percent owner, other: Director by Deputization 171 MAIN STREET, #671, LOS ALTOS CA 94022
Steven J. Kafka director, officer: Chief Executive Officer C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Andrew Elbardissi director 2210 FARADAY AVE #100, CARLSBAD CA 92008
Chris Wolfe officer: Chief Financial Officer 230 PARK AVENUE SOUTH, 11TH FLOOR, C/O CAPITAL Z PARTNERS, NEW YORK NY 10003
Kristina Burow 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Mara G. Aspinall director 7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718